Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

Neurology

Volumn 55, Issue 11 SUPPL. 4, 2000, Pages

  Nutt, J G ^a   Obeso, ^a   Reichmann, ^a   Olanow, ^a   Lieberman, ^a   Koller, ^a   Fahn, ^a   Gordin, ^a   Dingemanse, ^a   Brooks, ^a   Gu ttman, ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOL METHYLTRANSFERASE; ENTACAPONE; LEVODOPA; TOLCAPONE;

ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

CATECHOL O-METHYLTRANSFERASE; HUMANS; LEVODOPA; PARKINSONIAN DISORDERS;

EID: 0034642337     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone
2. COMT inhibitors: Pharmacokinetic and pharmacodynamic comparisons
3. Effect of peripheral catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
4. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies
5. Effect of supplemental carbidopa on bioavailability of L-DOPA
6. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
7. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled release levodopacarbidopa in volunteers
8. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
9. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
10. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with 'wearing-off' phenomenon: A multicentre, double-blind, randomized, placebo-controlled trial
11. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
12. Tolcapone at 100 or 200 mg tid for 6 weeks
13. Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: A double-blind, placebocontrolled, multicenter trial
14. Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients
15. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients
16. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
17. Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study
18. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients